Ovid Therapeutics Inc. (OVID) SEC Filings & Earnings Calls

Capital dependency risk

“We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all.” · word for word

Profitability risk

“We expect to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.” · word for word

Clinical trial failure risk

“Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, our drug candidates may not have favorable results in planned or future preclinical studies or clinical trials, or may not receive regulatory approval.” · word for word

CFO transition may cause short-term operational disruption, but no disagreement indicates orderly transition.

“Mr. Rona's departure was not the result of any disagreement with the Company on any matter relating to the Company’s accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices.” · word for word

Capital need risk

“We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all.” · word for word

Clinical failure risk

“All of our drug candidates are in clinical trials or preclinical development.” · word for word

Dependence on equity financing and dilutive capital raises

“The 2025 PIPE financing resulted in gross proceeds to us of up to $175.1 million... The 2026 PIPE resulted in gross proceeds to us of $60.0 million.” · word for word

CEO transition and key person risk

“Effective January 1, 2026, Ms. Alexander succeeded Dr. Levin as Chief Executive Officer and Dr. Levin remained Chairman of the Board.” · word for word

Dilution from PIPE financing may pressure stock price.

“Issuance of shares and pre-funded warrants to investors.”

FDA Disruption Risk

“the current administration has implemented substantial reductions in force at various government agencies including the FDA, and has implemented layoffs at the FDA, which could significantly reduce the FDA’s capacity to perform its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business.” · word for word

Funding Risk

“We have no products approved for commercial sale and have not generated any revenues from product sales to date. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings and additional funding from license and collaboration arrangements.” · word for word

Clinical Trial Risk

“The process of conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming.” · word for word

Clinical development risk remains for OV329 Phase 2 and KCC2 programs.

“OV329 Phase 2a initiation in Q2 2026; KCC2 first-in-human data expected Q4 2025.”

No approved products or revenue

“We have no drugs approved for commercialization and have never generated any revenue from drug sales.” · word for word

Need for additional capital

“We will require additional capital to finance our operations, which may not be available on acceptable terms, if at all.” · word for word

Clinical trial risk

“All of our current drug candidates are in early clinical or preclinical development and their risk of failure is high.” · word for word

Limited ability to raise capital via S-3

“As our public float is currently less than $75.0 million, we are currently subject to this limitation.” · word for word

Former lead candidate failed

“soticlestat failed to meet its primary endpoints in two Phase 3 trials ... Takeda announced discontinuation of the program.” · word for word

Extreme dilution risk

“The additional shares of Common Stock to be authorized by approval of the Authorized Shares Amendment would have rights identical to the currently outstanding shares of Common Stock... future issuance of shares of Common Stock... could have a dilutive effect on our earnings per share, book value per share, and the voting rights of stockholders.” · word for word

Going concern risk

“Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. To date we have no products approved for commercialization and have not generated any revenue from product sales.” · word for word

Governance risk - CEO self-dealing

“Jeremy M. Levin, DPhil, MB BChir is our Chief Executive Officer and the Chairman of the Board. Pursuant to the Purchase Agreement, Dr. Levin purchased (i) 71 shares of Series B Preferred Stock, (ii) Series A Warrants to purchase up to 47,333 shares of Common Stock and (iii) Series B Warrants to purchase up to 35,500 shares of Common Stock for an aggregate pu” · word for word